Ofirnoflast: A First-in-Class NEK7-Targeted Inhibitor of the NLRP3 Inflammasome
{{output}}
Ofirnoflast is a first-in-class, orally bioavailable NEK7 inhibitor currently undergoing Phase 2 clinical evaluation. It disrupts NLRP3 inflammasome assembly by targeting NEK7's scaffolding function-blocking complex formation independently of NLRP3 activation... ...
